SCHEMBL4924988

SCHEMBL4924988

Cc1ccc(O)c(NC(=O)Nc2cc(C(N)=O)ccc2O)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.57
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
CA9 Q16790 3/20 0.57
KCNMA1 Q12791 3/20 0.56
GAA P10253 6/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPT P10636 1/20 0.50
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
CXCR2 P25025 1/20 0.47
PARP1 P09874 1/20 0.46
F2 P00734 1/20 0.45
F10 P00742 1/20 0.45
PLAU P00749 1/20 0.45
PLAT P00750 1/20 0.45
HTT P42858 1/20 0.45
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27681865 0.93 CXCR2 (0.57) CA12CA1CA2CA9KCNMA1
SCHEMBL4927624 0.84 CA12 (0.51) CA12CA1CA2CA9KCNMA1
SCHEMBL4923902 0.83 RAB9A (0.51) CA12CA1CA2CA9GAA
SCHEMBL4927541 0.82 PLG (0.60) KCNMA1GAASMN1; SMN2NPC1TP53
SCHEMBL4915093 0.80 CA12 (0.48) CA12CA1CA2CA9KCNMA1
SCHEMBL8286030 0.80 KMT2A (0.61) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL4925227 0.79 RAB9A (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL4915647 0.79 LCK (0.50) CA12CA1CA2CA9SMN1; SMN2
SCHEMBL6029542 0.78 KCNMA1 (0.84) KCNMA1GAASMN1; SMN2MAPTNPC1
SCHEMBL4920330 0.78 MDM4 (0.46) CA12CA1CA2CA9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2008-10-30 US disclosed
EP-1796681-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF Genmedica Therapeutics SL (ES) 2007-06-20 EP disclosed
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof GENMEDICA THERAPEUTICS SL (ES) 2007-03-22 US disclosed
WO-2006013209-A2 COMPOUNDS FOR INHIBITING COPPER-CONTAINING AMINE OXIDASES AND USES THEREOF GENMEDICA THERAPEUTICS SL (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269282-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CA12 3438/4885CA1 2819/4885CA2 3279/4885
US-20070066646-A1 Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof AOC2, AOC3, AOC1 CA12 3541/4885CA1 3000/4885CA2 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.